Efficacy and safety of surufatinib in the treatment of thymic neuroendocrine tumors: a 102-case retrospective study.
For patients with advanced, progressive, well-differentiated TNETs, Surufatinib can be used as an option with a high mPFS and DCR. Moreover, the safety profile of surufatinib was found to be acceptable. These findings suggest that surufatinib could potentially serve as an innovative therapeutic option for this particular patient population.
Authors
- Dan Huang (ORCID: https://orcid.org/0000-0002-7001-1325)
- Fengzhen Chen (ORCID: https://orcid.org/0009-0009-3673-5395)
- Jie Chen (ORCID: https://orcid.org/0009-0002-1536-2007)
- Xuebing Jia (ORCID: https://orcid.org/0009-0000-9538-8594)
- Yun Liang (ORCID: https://orcid.org/0000-0003-3759-2997)
- Zhichen Sun (ORCID: https://orcid.org/0000-0001-9885-0553)
- Junyan Xu (ORCID: https://orcid.org/0009-0008-3582-847X)
Institutions
- Shanghai Medical College of Fudan University (CN)
- Fudan University Shanghai Cancer Center (CN)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-03-30
- DOI
- https://doi.org/10.1093/oncolo/oyaf072
- Citations
- 1
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- National Natural Science Foundation of China